I don't advocate "stops" either but the reason PTIE slid so much over the past two weeks is that the Nasdaq biotech index is being rebalanced and around 500,000 PTIE shares had to be sold due to its reduced market cap. It looks as if they may now be finished and the pressure should be off.
ooohh man you must be under the influence of green dreams
now why will some body pay more than it is require for some thing that don't have value
pomp and dump as all ways
From PharmaTimesOnline - 12/18/13
The US opioid market is dominated by non tamper-resistant formulations, but the Food and Drug Administration’s promotion of TRF therapies could well result in the departure of non-TRF treatments from the market, say new forecasts.
Purdue Pharma’s Oxycontin is the only opioid pain treatment among the 50 top-selling pharmaceuticals in the USA, and unless the FDA mandates TRF therapies, further genericisation and lack of novel mechanism of actions (MOAs) will ensure opioids are absent from the top 50 by 2018, warns the study, from Frost & Sullivan.
Nevertheless, it sees large opportunities for tamper-resistant technologies, as well as combination therapies to minimise side effects from opioid products.
With 25 million Americans suffering from moderate-to-severe chronic pain that interferes with their daily lives, orally-delivered pain products will continue to dominate the market, says the study. Oxycontin leads this category, generating $2.77 billion in sales in 2012, while the transdermal category was led by Johnson & Johnson’s Duragesic (fentanyl transdermal) patch for cancer-induced pain and Endo’s Lidoderm (lidocaine) patch for chronic pain.
FDA’s push for abuse-deterrent formulations will also spell a boom for extended-release opioids. So far, in spite of the continued development of extended-release formulations, immediate-release products have dominated the market, with a 91% market share. This is partly due to the recent requirement for a risk evaluation mitigation strategy (REMS) for extended-release formulations. However, with FDA favouring TRF therapies, extended-release drugs will find greater favour among drug developers, says F&S.
“Another outcome of the FDA’s endorsement of TRFs is the flooding of the pain therapy pipeline with new TRF opioid-based therapies,” says Jennifer Lazar Brice, life sciences global research director at F&S. “In this scenario, Pfizer has significant opportunity to grow, with its broad pipeline of oral (TRFs), transdermals and IV candidates,” she adds.
As opioids are the mainstay of pain treatment, there is a substantial market for a therapy for opioid-induced constipation. Nektar Therapeutics’ NKTR-118, a Phase III candidate for this condition, will be of particular interest, the study notes.
It also expects companies which develop a novel, non-opioid MOA therapy to gain particularly in this market. Healthcare providers will be keenly watching developments in calcitonin gene-related (CGRP-targeted therapies.
“Overall, the future of the pain market is heavily dependent upon the FDA’s decision to remove non-TRF generic therapies from the market. This move will create a huge opportunity for new TRF therapies to remain branded,” says Ms Lazar Brice.
Remind me - what do they do all day other than count their money. ad to it form 4. Remi Barbier buys 39637shares on 12/12/13 You should try ti you might like it!!!
Is that all you have to do is sit around and complain? This is the way companies operate. if you don't like it you can put your money in a bank or under your mattress. Writing letters may help your frustrations , but does little good other than that. Go take a laxative and have a good BM.
It's that time of year again. I wonder how many millions the directors will vote themselves this year. Well they keep getting away with it year after year and they avoid CCs like the plague so that nobody can ask any questions so my guess is bigger than ever. Remind me - what do they do all day other than count their money. As far as I know the company has done nothing this year except refuse to amend the royalty rates with PFE. Well that's got to be worth $5m. But you my fellow shareholders don't care do you? But if you do Peter Roddy's email address is freely available.
Even after recent runup, this stock is extremely undervalued. Using conservative market penetration rates starting in 2016, this is worth at least $8 right now. This is excluding the hydrocodone, hydromorphone and oxymorphone revenue / royalty potential (rights which PFE relinquished recently)
Part of the reason PTIE is fluctuating widely is the practice of some small investors setting "stops" on their purchases to avoid getting wiped out. The MM's love to drop the price and wipe out the stops and quickly bring the price back up. This is really illegal but the MM's are not afraid under this administration. Around 1990 they were hit with a billion dollar fine for this and other shady practices.
I mean seriously, it's gonna be a long time before PTIE gets remoxy close to the point where ACUR has Oxecta (oxycodone or Nexafed
My guess is that PTIE has partnered with someone with respect to developingthe new abuse-resistant formulations of hydrocodone, hydromorphone and oxymorphone that Pfizer #$%$ back
With more than two years to go before a possible FDA approval of Remoxy it's hard to imagine that there's going to be a concerted upward run.
I saw on another board that Purdue earlier in the year had granted Actavis a licence to sell a limited number of bottles of Oxycontin's new formulation from late 2014 if they can get it approved by the FDA. That seems a little odd doesn't it? Why would they do that. That suggests that generic Oxy might be just around the corner.